Interferon alpha in hepatitis C: a cytokine for reducing fibrosis progression.
Poynard
T
T
Department Hepato-Gastro-Enterology, Hôpital Pitié-Salpêtrière, Paris, France.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000150:complications / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins